JP2023530663A5 - - Google Patents
Info
- Publication number
- JP2023530663A5 JP2023530663A5 JP2022576392A JP2022576392A JP2023530663A5 JP 2023530663 A5 JP2023530663 A5 JP 2023530663A5 JP 2022576392 A JP2022576392 A JP 2022576392A JP 2022576392 A JP2022576392 A JP 2022576392A JP 2023530663 A5 JP2023530663 A5 JP 2023530663A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- antigen
- binding protein
- seq
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063036092P | 2020-06-08 | 2020-06-08 | |
| US63/036,092 | 2020-06-08 | ||
| PCT/US2021/036347 WO2021252455A1 (en) | 2020-06-08 | 2021-06-08 | ANTI-TGFβ ANTIBODIES AND THERAPEUTIC USES THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023530663A JP2023530663A (ja) | 2023-07-19 |
| JP2023530663A5 true JP2023530663A5 (enExample) | 2024-12-16 |
| JP7798805B2 JP7798805B2 (ja) | 2026-01-14 |
Family
ID=76708478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022576392A Active JP7798805B2 (ja) | 2020-06-08 | 2021-06-08 | 抗ＴＧＦβ抗体及びその治療的使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220119513A1 (enExample) |
| EP (1) | EP4161654A1 (enExample) |
| JP (1) | JP7798805B2 (enExample) |
| KR (1) | KR20230022974A (enExample) |
| CN (1) | CN115803342A (enExample) |
| AU (1) | AU2021287868A1 (enExample) |
| BR (1) | BR112022024195A2 (enExample) |
| CA (1) | CA3186707A1 (enExample) |
| CO (1) | CO2023000068A2 (enExample) |
| DK (1) | DK202370008A1 (enExample) |
| MX (1) | MX2022015609A (enExample) |
| PH (1) | PH12022500030A1 (enExample) |
| WO (1) | WO2021252455A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116096741B (zh) | 2020-07-10 | 2024-10-18 | 因外泰克斯公司 | 用于延长治疗剂在猫科动物中的半衰期的组合物和使用方法 |
| CA3194936A1 (en) | 2020-09-28 | 2022-03-31 | Zoetis Services Llc | Canine antibody variants |
| CA3232382A1 (en) * | 2021-09-27 | 2023-03-30 | Zoetis Services Llc | Anti- tgf.beta.1,2,3 antibodies and therapeutic uses thereof |
| KR20250137204A (ko) | 2022-12-27 | 2025-09-17 | 인베티엑스 인코포레이티드 | 신생아 fc 수용체(fcrn)에 대한 결합이 변경된 폴리펩타이드 및 사용 방법 |
| AU2023415535A1 (en) | 2022-12-27 | 2025-07-10 | Invetx, Inc. | Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use |
| CN121002059A (zh) | 2023-01-20 | 2025-11-21 | 因外泰克斯公司 | 用于伴侣动物的双特异性结合剂 |
| CN117106082B (zh) * | 2023-09-15 | 2024-10-29 | 成都蓉生药业有限责任公司 | 一种抗TGFβ的人源化纳米抗体 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5350576A (en) | 1991-09-13 | 1994-09-27 | Mycogen Corporation | Bacillus thuringiensis isolates for controlling acarides |
| US6194167B1 (en) | 1997-02-18 | 2001-02-27 | Washington State University Research Foundation | ω-3 fatty acid desaturase |
| MXPA01009363A (es) | 1999-03-18 | 2002-06-04 | Merck Patent Gmbh | Proteina para bloquear la adhesion de plaquetas. |
| US6492497B1 (en) * | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| EP1130098A3 (en) | 2000-02-29 | 2003-09-10 | Pfizer Products Inc. | Mammalian osteoregulins |
| US20030031671A1 (en) | 2001-08-01 | 2003-02-13 | Sydney Welt | Methods of treating colon cancer utilizing tumor-specific antibodies |
| CA2469833C (en) | 2001-12-21 | 2008-05-20 | Idexx Laboratories, Inc. | Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them |
| CA2632799A1 (en) * | 2005-12-23 | 2007-07-05 | Eli Lilly And Company | Tgf-beta binding compositions |
| WO2013134365A1 (en) * | 2012-03-08 | 2013-09-12 | Ludwig Institute For Cancer Research Ltd | TGF-β1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF |
| JP6495884B2 (ja) * | 2013-03-11 | 2019-04-03 | ジェンザイム・コーポレーション | 改変抗ｔｇｆベータ抗体および抗原結合フラグメント |
| TWI733661B (zh) * | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
| TWI726870B (zh) * | 2015-03-04 | 2021-05-11 | 美商健臻公司 | 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體 |
| TW202506185A (zh) * | 2017-01-20 | 2025-02-16 | 法商賽諾菲公司 | 抗TGF-β抗體及其用途 |
| US20200392219A1 (en) * | 2017-05-08 | 2020-12-17 | Trustees Of Tufts College | Extracellular vesicles comprising membrane-tethered tgf-beta, compositions and methods of use thereof |
| EP3877055A1 (en) * | 2018-11-05 | 2021-09-15 | Ludwig Institute for Cancer Research Ltd | Humanized and variant tgf-beta1 specific antibodies and methods and uses thereof |
-
2021
- 2021-06-07 US US17/341,212 patent/US20220119513A1/en active Pending
- 2021-06-08 AU AU2021287868A patent/AU2021287868A1/en active Pending
- 2021-06-08 MX MX2022015609A patent/MX2022015609A/es unknown
- 2021-06-08 CN CN202180049397.1A patent/CN115803342A/zh active Pending
- 2021-06-08 BR BR112022024195A patent/BR112022024195A2/pt unknown
- 2021-06-08 EP EP21736479.3A patent/EP4161654A1/en active Pending
- 2021-06-08 CA CA3186707A patent/CA3186707A1/en active Pending
- 2021-06-08 WO PCT/US2021/036347 patent/WO2021252455A1/en not_active Ceased
- 2021-06-08 KR KR1020237000721A patent/KR20230022974A/ko active Pending
- 2021-06-08 PH PH1/2022/500030A patent/PH12022500030A1/en unknown
- 2021-06-08 JP JP2022576392A patent/JP7798805B2/ja active Active
-
2023
- 2023-01-05 CO CONC2023/0000068A patent/CO2023000068A2/es unknown
- 2023-01-06 DK DKPA202370008A patent/DK202370008A1/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7041516B2 (ja) | 共通軽鎖を有する二重特異性抗体又は抗体混合物 | |
| JP2022079549A5 (enExample) | ||
| JP2020505919A5 (enExample) | ||
| CN111018987B (zh) | 一种能与人内皮素受体特异性结合的抗体及其应用 | |
| JP2008542278A5 (enExample) | ||
| KR102967396B1 (ko) | Gipr 항체 및 이와 glp-1의 융합 단백질, 및 그의 약학 조성물 및 적용 | |
| JP7533897B2 (ja) | 融合タンパク質およびその使用 | |
| JP2024531409A5 (enExample) | ||
| HRP20110187T1 (hr) | Multispecifične deimunizirane tvari koje vežu cd3 | |
| JP2022540083A5 (enExample) | ||
| CN113354730B (zh) | 一种抗新型冠状病毒的单克隆抗体及其应用 | |
| JP2023093753A5 (enExample) | ||
| JP2010509931A5 (enExample) | ||
| JP2013539369A5 (enExample) | ||
| CN110869390A (zh) | 抗pd-l1抗体及其用途 | |
| JP2023506750A5 (enExample) | ||
| JP2020505927A5 (enExample) | ||
| TW202613177A (zh) | Gipr抗體及其與glp-1的融合蛋白質，以及其藥物組合物和應用 | |
| JP2023549851A5 (enExample) | ||
| CN1381461A (zh) | 抗人肝癌单克隆抗体HAb18轻、重链可变区基因及其应用 | |
| JP2023508674A5 (enExample) | ||
| JP2018512124A5 (enExample) | ||
| JP2021517459A5 (enExample) | ||
| JP2018508218A5 (enExample) | ||
| RU2017134042A (ru) | ДИМЕРЫ SCFV-FC, КОТОРЫЕ СВЯЗЫВАЮТСЯ С ТРАНСФОРМИРУЮЩИМ ФАКТОРОМ РОСТА β1 С ВЫСОКОЙ АФФИННОСТЬЮ, АВИДНОСТЬЮ И СПЕЦИФИЧНОСТЬЮ |